6 results on '"Chotoo S"'
Search Results
2. Evaluation of granulated BGO, GSO:Ce, YAG:Ce, CaF~2:Eu and ZnS:Ag for alpha/beta pulse shape discrimination in a flow-cell radiation detector
- Author
-
DeVol, T. A., Chotoo, S. B., and Field, R. A.
- Published
- 1999
- Full Text
- View/download PDF
3. Critical assessment of infants born to mothers with drug resistant tuberculosis.
- Author
-
Loveday M, Gandhi NR, Khan PY, Theron G, Hlangu S, Holloway K, Chotoo S, Singh N, and Marais BJ
- Abstract
Background: There have been no detailed descriptions of infants born to mothers treated for drug resistant TB in pregnancy. Critical case history assessment is important to identify risks and guide clinical practice., Methods: In a cohort of pregnant women with multidrug or rifampicin resistant (MDR/RR)-TB enrolled between 1 January 2013 and 31 December 2022, we followed mother-infant pairs until the infant was 12 months old. We performed critical case history assessments to explore potential mechanisms of Mycobacterium tuberculosis transmission to the infant, and to describe the clinical presentation and disease trajectories observed in infants diagnosed with TB., Findings: Among 101 mother-infant pairs, 23 (23%) included infants diagnosed with TB disease; 16 were clinically diagnosed and seven had microbiological confirmation (five MDR/RR-TB, two drug-susceptible TB). A positive maternal sputum culture at the time of delivery was significantly associated with infant TB risk (p = 0.023). Of the 12 infants diagnosed with TB in the first three months of life, seven (58%) of the mothers were culture positive at delivery; of whom four reported poor TB treatment adherence. However, health system failures, including failing to diagnose and treat maternal MDR/RR-TB, inadequate screening of newborns at birth, not providing appropriate TB preventive therapy (TPT), and M. tuberculosis transmission from non-maternal sources also contributed to TB development in infants., Interpretation: Infants born to mothers with MDR/RR-TB are at greatest risk if maternal adherence to MDR/RR-TB treatment or antiretroviral therapy (ART) is sub-optimal. In a high TB incidence setting, infants are also at risk of non-maternal household and community transmission. Ensuring maternal TB diagnosis and appropriate treatment, together with adequate TB screening and prevention in all babies born to mothers or households with TB will minimise the risk of infant TB disease development., Funding: South African Medical Research Council., Competing Interests: We declare no competing interests., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
4. Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa.
- Author
-
Loveday M, Hughes J, Sunkari B, Master I, Hlangu S, Reddy T, Chotoo S, Green N, and Seddon JA
- Subjects
- Antitubercular Agents therapeutic use, Child, Female, Humans, Infant, Pregnancy, Pregnant Women, South Africa epidemiology, Rifampin, Tuberculosis drug therapy
- Abstract
Background: Data on safety and efficacy of second-line tuberculosis drugs in pregnant women and their infants are severely limited due to exclusion from clinical trials and expanded access programs., Methods: Pregnant women starting treatment for multidrug/rifampicin-resistant (MDR/RR)-tuberculosis at King Dinuzulu Hospital in KwaZulu-Natal, South Africa, from 1 January 2013 to 31 December 2017, were included. We conducted a record review to describe maternal treatment and pregnancy outcomes, and a clinical assessment to describe infant outcomes., Results: Of 108 pregnant women treated for MDR/RR-tuberculosis, 88 (81%) were living with human immunodeficiency virus.. Favorable MDR/RR-tuberculosis treatment outcomes were reported in 72 (67%) women. Ninety-nine (91%) of the 109 babies were born alive, but overall, 52 (48%) women had unfavorable pregnancy outcomes. Fifty-eight (54%) women received bedaquiline, and 49 (45%) babies were exposed to bedaquiline in utero. Low birth weight was reported in more babies exposed to bedaquiline compared to babies not exposed (45% vs 26%; P = .034). In multivariate analyses, bedaquiline and levofloxacin, drugs often used in combination, were both independently associated with increased risk of low birth weight. Of the 86 children evaluated at 12 months, 72 (84%) had favorable outcomes; 88% of babies exposed to bedaquiline were thriving and developing normally compared to 82% of the babies not exposed., Conclusions: MDR/RR-tuberculosis treatment outcomes among pregnant women were comparable to nonpregnant women. Although more babies exposed to bedaquiline were of low birth weight, over 80% had gained weight and were developing normally at 1 year., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2021
- Full Text
- View/download PDF
5. Individualized Treatment of Multidrug-resistant Tuberculosis Using Whole-Genome Sequencing and Expanded Drug-Susceptibility Testing.
- Author
-
Dookie N, Padayatchi N, Lessells RJ, Naicker CL, Chotoo S, and Naidoo K
- Subjects
- Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use, Drug Resistance, Multiple, Bacterial genetics, Genome, Bacterial, Humans, Microbial Sensitivity Tests, Mycobacterium tuberculosis genetics, Pharmaceutical Preparations, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant genetics
- Abstract
A case of multidrug-resistant tuberculosis is presented. It highlights the role of whole-genome sequencing, expanded phenotypic drug susceptibility testing, and enhanced case management, offering a more complete understanding of drug susceptibility to Mycobacterium tuberculosis. This approach guides an effective individualized treatment strategy that results in rapid sustained culture conversion., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2020
- Full Text
- View/download PDF
6. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
- Author
-
Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, Padanilam X, Enwerem M, Chotoo S, Singh N, Hughes J, Variava E, Ferreira H, Te Riele J, Ismail N, Mohr E, Bantubani N, and Conradie F
- Subjects
- Adult, Anti-HIV Agents administration & dosage, Antitubercular Agents administration & dosage, Clofazimine administration & dosage, Diarylquinolines adverse effects, Drug Resistance, Bacterial, Drug Therapy, Combination, Female, Fluoroquinolones therapeutic use, HIV Infections complications, HIV Infections drug therapy, Humans, Levofloxacin administration & dosage, Linezolid administration & dosage, Male, Middle Aged, Poisson Distribution, South Africa, Treatment Outcome, Diarylquinolines administration & dosage, Extensively Drug-Resistant Tuberculosis drug therapy, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
South African patients with rifampicin-resistant tuberculosis (TB) and resistance to fluoroquinolones and/or injectable drugs (extensively drug-resistant (XDR) and preXDR-TB) were granted access to bedaquiline through a clinical access programme with strict inclusion and exclusion criteria.PreXDR-TB and XDR-TB patients were treated with 24 weeks of bedaquiline within an optimised, individualised background regimen that could include levofloxacin, linezolid and clofazimine as needed. 200 patients were enrolled: 87 (43.9%) had XDR-TB, 99 (49.3%) were female and the median age was 34 years (interquartile range (IQR) 27-42). 134 (67.0%) were living with HIV; the median CD4
+ count was 281 cells·μL-1 (IQR 130-467) and all were on antiretroviral therapy.16 out of 200 patients (8.0%) did not complete 6 months of bedaquiline: eight were lost to follow-up, six died, one stopped owing to side effects and one was diagnosed with drug-sensitive TB. 146 out of 200 patients (73.0%) had favourable outcomes: 139 (69.5%) were cured and seven (3.5%) completed treatment. 25 patients (12.5%) died, 20 (10.0%) were lost from treatment and nine (4.5%) had treatment failure. 22 adverse events were attributed to bedaquiline, including a QT interval corrected using the Fridericia formula (QTcF) >500 ms (n=5), QTcF increase >50 ms from baseline (n=11) and paroxysmal atrial flutter (n=1).Bedaquiline added to an optimised background regimen was associated with a high rate of successful treatment outcomes for this preXDR-TB and XDR-TB cohort., Competing Interests: Conflict of interest: N. Ndjeka reports non-financial support (donation of bedaquiline) from Janssen Pharmaceutica, during the conduct of the study; and Janssen Pharmaceutica provided support to the SA TB Programme: funding for training, provision of ECG machines and hearing tests machines. N Ndjeka is an official within the South African Department of Health; his responsibilities include recommending guidelines for drug-resistant TB treatment. Conflict of interest: K. Schnippel has nothing to disclose. Conflict of interest: I. Master has nothing to disclose. Conflict of interest: G. Meintjes has nothing to disclose. Conflict of interest: G. Maartens has nothing to disclose. Conflict of interest: R. Romero has nothing to disclose. Conflict of interest: X. Padanilam has nothing to disclose. Conflict of interest: M. Enwerem has nothing to disclose. Conflict of interest: S. Chotoo has nothing to disclose. Conflict of interest: N. Singh has nothing to disclose. Conflict of interest: J. Hughes has nothing to disclose. Conflict of interest: E. Variava has nothing to disclose. Conflict of interest: H. Ferreira has nothing to disclose. Conflict of interest: J. te Riele has nothing to disclose. Conflict of interest: N. Ismail has nothing to disclose. Conflict of interest: E. Mohr has nothing to disclose. Conflict of interest: N. Bantubani has nothing to disclose. Conflict of interest: F. Conradie reports sponsorship for travel and registration for conferences from Janssen Pharmacuetica, outside the submitted work., (Copyright ©ERS 2018.)- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.